Leerink Swann Starts Sage Therapeutics (SAGE) at Outperform

Leerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $33.40 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Needham Starts Lantronix, Inc. (LTRX) at Buy
• Freedom Broker Starts Comcast Corp (CMCSA) at Hold